Cellosaurus PK-1 (CVCL_4717)

Cell line name PK-1
Synonyms PK1
Accession CVCL_4717
Resource Identification Initiative To cite this cell line use: PK-1 (RRID:CVCL_4717)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: 48 hours (PubMed=3547771; PubMed=6205469); 24.1 hours (PubMed=8872523).
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Derived from metastatic site: Liver.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_5146 (KLM-1)CVCL_0B31 (RPK-1)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): PubMed=25877200; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO12
D13S3179,10
D16S53912
D18S5113
D21S1131
D3S135815
D5S81811,12
D7S82011
D8S117910,15
FGA22,24
Penta D9
Penta E9,20
TH019,10 (PubMed=25877200; RCB)
9 (TKG)
TPOX9,11
vWA15,19
Publications

PubMed=6205469; DOI=10.1620/tjem.143.33
Kobari M., Matsuno S., Sato T., Kan M., Tachibana T.
Establishment of a human pancreatic cancer cell line and detection of pancreatic cancer associated antigen.
Tohoku J. Exp. Med. 143:33-46(1984)

PubMed=3547771; DOI=10.1620/tjem.150.231
Kobari M., Hisano H., Matsuno S., Sato T., Kan M., Tachibana T.
Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs.
Tohoku J. Exp. Med. 150:231-248(1986)

PubMed=8872523; DOI=10.1007/BF02787375
Kimura Y., Kobari M., Yusa T., Sunamura M., Kimura M., Shimamura H., Matsuno S.
Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1).
Int. J. Pancreatol. 20:43-50(1996)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122
Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A.
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Biochem. Biophys. Res. Commun. 421:98-104(2012)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

Cross-references
Cell line collections RCB; RCB1972
TKG; TKG 0239
Cell line databases/resources CCLE; PK1_PANCREAS
Ontologies BTO; BTO:0004854
CLO; CLO_0050105
Biological sample resources BioSample; SAMN03472897
Gene expression databases GEO; GSM887515
GEO; GSM888597
GEO; GSM1588614
Polymorphism and mutation databases Cosmic; 707253
Cosmic; 1066176
Cosmic; 1644297
Cosmic; 2046536